Table 2.

Description of Clozapine (n = 1004) and Olanzapine (n = 2256) and Samples by Non-Time Changing Characteristics, Based on Prescription Registers for the Whole of Sweden, Reflecting First Withdrawal of Each Drug Between January 1, 2006 to December 31, 2010

ClozapineOlanzapine
Count (%)Count (%)
Year of treatment start
 2006204 (20.32)664 (29.41)
 2007194 (19.32)490 (21.7)
 2008201 (20.02)360 (15.94)
 2009213 (21.22)372 (16.47)
 2010192 (19.12)372 (16.47)
Gender
 Male663 (66.04)1385 (61.34)
 Female341 (33.96)873 (38.66)
Born in Sweden797 (79.38)1721 (76.22)
Duration of treatment
 8 weeks–1 year224 (22.31)1001 (44.33)
 1–3 years446 (44.42)788 (34.90)
 3 years or more334 (33.27)469 (20.77)
Educational attainment at treatment start
 ≤9 years343 (34.16)702 (31.09)
 10–12 years576 (57.37)1317 (58.33)
 University or higher53 (5.28)172 (7.62)
 Missing32 (3.19)67 (2.97)
Age at drug start (years)
 18 < 28206 (20.52)295 (13.06)
 28 < 38331 (32.97)578 (25.6)
 38 < 48319 (31.77)920 (40.74)
 48 < 58148 (14.74)465 (20.59)
Start periods
 Before 2007398 (39.64)1154 (51.11)
 After 2008606 (60.36)1104 (48.89)
Period of psychotic disorders diagnosis
 1970–198234 (3.39)102 (4.52)
 1983–1991137 (13.65)295 (13.06)
 1992–2001291 (28.98)585 (25.91)
 2002–542 (53.98)1276 (56.51)
Age at psychotic disorders diagnosis
 18 < 28536 (53.39)861 (38.13)
 28 < 38310 (30.88)763 (33.79)
 38 < 48141 (14.04)527 (23.34)
 48 < 5817 (1.69)107 (4.74)
ClozapineOlanzapine
Count (%)Count (%)
Year of treatment start
 2006204 (20.32)664 (29.41)
 2007194 (19.32)490 (21.7)
 2008201 (20.02)360 (15.94)
 2009213 (21.22)372 (16.47)
 2010192 (19.12)372 (16.47)
Gender
 Male663 (66.04)1385 (61.34)
 Female341 (33.96)873 (38.66)
Born in Sweden797 (79.38)1721 (76.22)
Duration of treatment
 8 weeks–1 year224 (22.31)1001 (44.33)
 1–3 years446 (44.42)788 (34.90)
 3 years or more334 (33.27)469 (20.77)
Educational attainment at treatment start
 ≤9 years343 (34.16)702 (31.09)
 10–12 years576 (57.37)1317 (58.33)
 University or higher53 (5.28)172 (7.62)
 Missing32 (3.19)67 (2.97)
Age at drug start (years)
 18 < 28206 (20.52)295 (13.06)
 28 < 38331 (32.97)578 (25.6)
 38 < 48319 (31.77)920 (40.74)
 48 < 58148 (14.74)465 (20.59)
Start periods
 Before 2007398 (39.64)1154 (51.11)
 After 2008606 (60.36)1104 (48.89)
Period of psychotic disorders diagnosis
 1970–198234 (3.39)102 (4.52)
 1983–1991137 (13.65)295 (13.06)
 1992–2001291 (28.98)585 (25.91)
 2002–542 (53.98)1276 (56.51)
Age at psychotic disorders diagnosis
 18 < 28536 (53.39)861 (38.13)
 28 < 38310 (30.88)763 (33.79)
 38 < 48141 (14.04)527 (23.34)
 48 < 5817 (1.69)107 (4.74)
Table 2.

Description of Clozapine (n = 1004) and Olanzapine (n = 2256) and Samples by Non-Time Changing Characteristics, Based on Prescription Registers for the Whole of Sweden, Reflecting First Withdrawal of Each Drug Between January 1, 2006 to December 31, 2010

ClozapineOlanzapine
Count (%)Count (%)
Year of treatment start
 2006204 (20.32)664 (29.41)
 2007194 (19.32)490 (21.7)
 2008201 (20.02)360 (15.94)
 2009213 (21.22)372 (16.47)
 2010192 (19.12)372 (16.47)
Gender
 Male663 (66.04)1385 (61.34)
 Female341 (33.96)873 (38.66)
Born in Sweden797 (79.38)1721 (76.22)
Duration of treatment
 8 weeks–1 year224 (22.31)1001 (44.33)
 1–3 years446 (44.42)788 (34.90)
 3 years or more334 (33.27)469 (20.77)
Educational attainment at treatment start
 ≤9 years343 (34.16)702 (31.09)
 10–12 years576 (57.37)1317 (58.33)
 University or higher53 (5.28)172 (7.62)
 Missing32 (3.19)67 (2.97)
Age at drug start (years)
 18 < 28206 (20.52)295 (13.06)
 28 < 38331 (32.97)578 (25.6)
 38 < 48319 (31.77)920 (40.74)
 48 < 58148 (14.74)465 (20.59)
Start periods
 Before 2007398 (39.64)1154 (51.11)
 After 2008606 (60.36)1104 (48.89)
Period of psychotic disorders diagnosis
 1970–198234 (3.39)102 (4.52)
 1983–1991137 (13.65)295 (13.06)
 1992–2001291 (28.98)585 (25.91)
 2002–542 (53.98)1276 (56.51)
Age at psychotic disorders diagnosis
 18 < 28536 (53.39)861 (38.13)
 28 < 38310 (30.88)763 (33.79)
 38 < 48141 (14.04)527 (23.34)
 48 < 5817 (1.69)107 (4.74)
ClozapineOlanzapine
Count (%)Count (%)
Year of treatment start
 2006204 (20.32)664 (29.41)
 2007194 (19.32)490 (21.7)
 2008201 (20.02)360 (15.94)
 2009213 (21.22)372 (16.47)
 2010192 (19.12)372 (16.47)
Gender
 Male663 (66.04)1385 (61.34)
 Female341 (33.96)873 (38.66)
Born in Sweden797 (79.38)1721 (76.22)
Duration of treatment
 8 weeks–1 year224 (22.31)1001 (44.33)
 1–3 years446 (44.42)788 (34.90)
 3 years or more334 (33.27)469 (20.77)
Educational attainment at treatment start
 ≤9 years343 (34.16)702 (31.09)
 10–12 years576 (57.37)1317 (58.33)
 University or higher53 (5.28)172 (7.62)
 Missing32 (3.19)67 (2.97)
Age at drug start (years)
 18 < 28206 (20.52)295 (13.06)
 28 < 38331 (32.97)578 (25.6)
 38 < 48319 (31.77)920 (40.74)
 48 < 58148 (14.74)465 (20.59)
Start periods
 Before 2007398 (39.64)1154 (51.11)
 After 2008606 (60.36)1104 (48.89)
Period of psychotic disorders diagnosis
 1970–198234 (3.39)102 (4.52)
 1983–1991137 (13.65)295 (13.06)
 1992–2001291 (28.98)585 (25.91)
 2002–542 (53.98)1276 (56.51)
Age at psychotic disorders diagnosis
 18 < 28536 (53.39)861 (38.13)
 28 < 38310 (30.88)763 (33.79)
 38 < 48141 (14.04)527 (23.34)
 48 < 5817 (1.69)107 (4.74)
Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close